Kidney Disease Screening Model

About Fluicell

Fluicell is pioneering a new paradigm in tissue engineering with its proprietary Nexocyte™ platform, which leverages twenty years of R&D and its Biopixlar bioprinting technology to create functional tissues with single-cell precision. The company is advancing a pipeline focused on tissue-based therapeutics for type 1 diabetes and complex in vitro models for cardiac toxicity and kidney disease screening. By enabling the design and production of tailored biological tissues, Fluicell aims to transform the treatment of chronic diseases and accelerate drug development for its pharmaceutical partners.

Therapeutic Areas